European CHMP recommends paediatric license extension and new strength of rivaroxaban (Xarelto)

The license extension, treatment of VTE and prevention of VTE recurrence in term neonates, infants and toddlers, children, and adolescents aged < 18 years after at least 5 days of initial parenteral anticoagulation treatment, is supported by a new 1 mg/ml oral suspension.

Source:

European Medicines Agency